On March 28, 2020, the FDA authorized the use of hydroxychloroquine and chloroquine under an emergency use authorization at the discretion of physicians caring for COVID-19 patients. The 7th edition of the Chinese guidelines also includes interferon, ribavirin or umifenovir against COVID-19.
Tarehe 28, Machi 2020, FDA ilitoa idhini ya matumizi ya dharura ya hydroxychloroquine na chloroquine kwa hiari ya madaktari wanaotibu watu wenye ugonjwa wa COVID-19. Miongozo ya toleo la 7 la Wachina pia inajumuisha matumizi ya interferon, ribavirin au umifonovir ili kuzuia COVID-19.